Diabetes Research and Clinical Practice
Volume 68, Issue 2 , Pages 96-103 , May 2005

Optimal use of quick-acting insulin analogue in combination with basal insulin and its long-term effect in Japanese children and adolescents with type 1 diabetes

Received 7 May 2004 ,Revised 21 July 2004 ,Accepted 19 August 2004.

References 

  1. The Diabetes Control and Complications Trial Research Group, Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabets control and Complications Trial, J. Pediatr. 125 (1994) 177–188.
  2. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J. Pediatr. 2001;139:804–812
  3. H.B. Mortensen, J. Villumsen, A.A. Volund, K.E. Petersen, J. Nerup, for the Danish Study Group of Diabetes in Childhood, Relationship between insulin injection regimen and metabolic control in young Danish type 1 diabetic patients, Diabet. Med. 9 (1992) 834–839.
  4. H.B. Mortensen, P. Houggaard, for the Hvidore Study Group on Childhood Diabetes, Comparison of metabolic control in a cross-section study of 2873 children and adolescents with insulin-dependent diabetes mellitus from 18 countries, Diabetes Care 20 (1997) 714–720.
  5. H.B. Mortensen, K.J. Robertson, H.-J., Aanstoot, T. Danne, R.W. Holl, P. Hougaard, et al., for the Hvidore Study Group on Childhood Diabetes, Insulin management and metabilic control of type 1 diabetes mellitus in childhood and adolescents in 18 countries, Diabet. Med. 15 (1998) 752–759.
  6. Vanelli M, Chiarelli F, Chiari G, Tuminis S, Costi G, diRicco L, et al. Metabolic control in children and adolescents with diabetes. J. Pediatr. Endocrinol. Metab. 1999;12:403–409
  7. Scotch Study Group for the Care of the Young Diabetics, Factors influencing glycemic control in young people with type-1 diabetes in Scotland: a population-based study (DIABAUD2), Diabetes Care 24 (2001) 239–244.
  8. R.W. Holl, P.G.F. Swift, B. Henrik, H.B. Mortensen, H. Lynggaard, P. Hougaard, et al., Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group, Eur. J. Pediatr. 162 (2003) 22–29.
  9. Norfelddt S, Ludviggson J. Adverse events in intensively treated children and adolescents with type 1 diabetes. Acta. Pediatr. 1999;88:1184–1193
  10. Urakami T, Kawamura T, Sugihara S, Miyamoto S, Amemiya S, Sasaki N, et al. A questionnaire survey on the use of quick-acting insulin analog in Japanese children and adolescents with type 1 diabetes. Pediatr. Int. 2004;46:285–290
  11. Rami B, Schober E. Post-prandial glycemia after regular and lispro insulin in children and adolescents with diabetes. Eur. J. Pediatr. 1997;156:838–840
  12. Rutledge KS, Chase HP. Klingensmith GJ, Walravens PA, Slover RH, Garg SK, Effectiveness of post-prandial Humalog in toddlers with diabetes. Pediatrics. 1997;100:968–972
  13. Mohn A, Matyka KA, Harris DA, Ross KM, Edge JA, Dunger DB. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Diabetes Care. 1999;22:27–32
  14. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur. J. Pediatr. 2000;159:483–488
  15. Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA. Strategies toward improved control during insulin lyspro therapy in IDDM: importance of basal insulin. Diabetes Care. 1997;20:1287–1289
  16. Sindaco PD, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E, et al. Use of the short-acting insulin analogue lyspro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet. Med. 1998;15:592–600
  17. Lalli C, Ciofetta M, Sindaco PD, Torlone E, Pampanelli S, Compagnucci P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at meal-time. Diabetes Care. 1999;22:468–477
  18. Tupola S, Komulainen J, Jaaskelainen J, Sipila I. Post-prandial insulin lispro versus human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet. Med. 2001;18:654–658
  19. Garcia L, Lamas C, Tuset MJ, Alonso M, Barrio R. Treatment with the insulin analogue lispro in children and adolescents with type 1 diabetes mellitus: evaluatin over a 3-year period. Diab. Nutr. Metab. 2002;15:7–13
  20. Martin D, Licha-Muntz G, Grasset E, Greneche MO, Nouet D, Francois L, et al. Efficacy of humalog injections before afternonn meal and their acceptance by children and adolescents with type 1 diabetes. Diabet. Med. 2002;19:1026–1031
  21. Ford-Adams ME, Murphy NP, Moore EJ, Edge JA, Ong KL, Watts AP, et al. Insulin lispro: a potential role in preventing nocturnal hypoglycemia in young children with diabetes mellitus. Diabet. Med. 2003;20:656–660
  22. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care. 1983;6:374–377
  23. Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet. Med. 2003;20:626–634
  24. N. Matsuura, Y. Yokota, N. Sasaki, S. Amemiya, for the Japanese Study Group of Insulin Therapy for the Chilhood and Adolescent diabetes (JSGIT), Insulin regimen and metabolic control in Japanese children with type 1 diabetes mellitus. Lesson from a multicenter collaborative study in Japan. J. Pediatr. Endocrinol. Metab. 16 (Suppl. 4) (2003) 924.

PII: S0168-8227(04)00282-7

doi: 10.1016/j.diabres.2004.08.012

Diabetes Research and Clinical Practice
Volume 68, Issue 2 , Pages 96-103 , May 2005

Article Tools

* Image Usage & Resolution